BSE filing, NSE: ZDHJERK. Summary written from the filing by ALFA Finder's alert engine.
Dhanvantri Jeevan Rekha Ltd: key numbers
- Share price
- ₹22.00
- Market cap
- ₹9.02 Cr
- Revenue (annual)
- ₹25.86 Cr
- Net profit (annual)
- ₹0.39 Cr
- P/E (TTM)
- 17.6×Sector 34.1×
- Promoter holding
- 19.65%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dhanvantri Jeevan Rekha Ltd
All →Dhanvantri Jeevan Rekha Other Announcement
Dhanvantri Jeevan Rekha Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with regulatory requirements.
Dhanvantri Jeevan Rekha Annual General Meeting
Dhanvantri Jeevan Rekha Ltd concluded its 33rd Annual General Meeting on September 29, 2026. Shareholders adopted financial statements and re-appointed two directors retiring by rotation.
Dhanvantri Jeevan Rekha Annual General Meeting
Dhanvantri Jeevan Rekha Ltd will hold its 33rd Annual General Meeting on September 29, 2026, via video conferencing to transact ordinary business including director re-appointments.
Dhanvantri Jeevan Rekha Annual General Meeting
Dhanvantri Jeevan Rekha Ltd announced its 33rd Annual General Meeting will be held on 29th September 2026. The board also approved the board report and appointment of a scrutinizer.
Dhanvantri Jeevan Rekha Board Meeting Date
Dhanvantri Jeevan Rekha Ltd has scheduled a board meeting on August 27, 2026, to convene the upcoming Annual General Meeting.
Dhanvantri Jeevan Rekha Q1 FY27 Results: Net Profit ₹0.2 Cr, Up 100.0% YoY
Dhanvantri Jeevan Rekha Ltd reported revenue from operations of ₹7.8 Cr (+41.8% YoY) and net profit of ₹0.2 Cr (+100.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.2 Cr · +100.0% YoY
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.